Skip to main content

Table 2 Clinical characteristics of 94 prostate cancer patients with rectal involvement (RI)

From: Factors associated with the survival of prostate cancer patients with rectal involvement

Clinical characteristics Synchronous rectal involvement at first cancer diagnosis Metachronous diagnosis of rectal involvement Total
(n = 63) (n = 31) (n = 94)
Age at rectal involvement 72(57-86)(63) 75(47-94)(27) 72.04(47-94)(90)
PSA at rectal involvement(ng/ml)# 113(3.9-7650) 32.75(0.008-1173) 463.10(0.008-7650)
Interval between primary tumor diagnosis and RI(months) & Race 0 40(6-216) 10.5(0-216)
Japan 46 16 62
USA 4 7 11
China 4 1 5
Brazil 2 0 2
France 0 1 1
Qatar 1 0 1
Pathological grade of RI    
well differentiated 2 0 2
moderately differentiated 10 2 12
poorly differentiated 43 20 63
ND 8 9 17
Histology of prostate cancer RI    
Prostate adenocarcinoma 61 29 90
Mixed type 4 2 6
Tumor extent at diagnosis of RI    
RI only 20 5 25(
Extrarectal metastases 28 16 44
ND 15 10 25
Prior therapy    
Hormonal therapy 0 28 28
Initial prostatectomy or radical radiotherapy 0 7 7
TURP 0 4 4
Type of rectal involvement    
I 7 2 9
II 34 10 44
III 8 4 12
IV 3 8 11
ND 12 6 18
Clinical symptoms    
Dysuria 14 4 18
Dyschezia 47 17 64
Hydronephrosis 14 3 17
Rectum bleeding 14 9 23
bowl obstruction 5 3 8
Misdiagnosized before therapy* 18 3 21
Treatment modalities after diagnosis of RI    
colostomy 9 10 19
TPE 11 1 12
RR 6 3 9
RT 9 4 13
HT 63 3 66
chemotherapy 0 3 3
TPE + HT@ 12 0 12
(RR or RT or TURP) + HT 12 0 12
  1. Values are given as median (min-max) or absolute numbers (number of patients).
  2. ND, not documented; RI, rectal involvement; TURP, transurethral resection; TPE, HT, hormone therapy; RT, radiotherapy; RR, rectum resection
  3. # PSA at rectal involvement (ng/ml) were available in 38 patients with synchronous and 16 patients with metachronous diagnosis.
  4. & Interval between primary tumor diagnosis and rectal involvement were available in 25 patients.
  5. *Before therapy, patients were misdiagnosized as rectal cancer, concomitant rectal and prostate cancer, and bladder cancer in 16, 3 and 2 patients respectively.
  6. @ 4 patients were given neoadjuvant HT + TPE + adjuvant HT
  7. “Mixed type” means prostate adenocarcinoma mixed with signet ring cell or ductal adenocarcinoma or papillary carcinoma.